Unprecedented overall survival in patients with 1L ESCC and PD-L1 scores ≥1%1
Key Efficacy Outcome: OS in PD-L1 ≥1%
16.8 months of median overall survival with TEVIMBRA + chemotherapy vs 9.6 months with placebo + chemotherapy
3-Year Exploratory Follow-Up: OS in PD-L1 ≥1%
Overall survival sustained over 3 years3
21.3% of patients were alive at 3 years with TEVIMBRA + chemotherapy (95% CI: 16.2-26.9) vs 14.3% with placebo + chemotherapy (95% CI: 10.1-19.2)
The 3-year OS analysis was exploratory in nature and was not powered to show statistical significance. Landmark OS rates were estimated using the Kaplan-Meier method.
Subgroup Analyses: OS in PD-L1 ≥1%
A consistent trend in overall survival favoring TEVIMBRA + chemotherapy across multiple key subgroups3
Efficacy analyses were descriptive only.
Consistent results seen with TEVIMBRA + chemotherapy regardless of race
‡The race subcategory “Other” included American Indian or Alaska Native, not reported, and unknown.
1L, first line; CRF, case report form; CPS, combined positive score; ECOG, Eastern Cooperative Oncology Group; ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; IRT, interactive response technology; mOS, median overall survival; ORR, overall response rate; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; PS, performance status.
References: 1. TEVIMBRA. Prescribing Information. San Mateo, CA: Beigene, Ltd.; 2025.
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 22, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
3. Xu J, Kato K, Hubner R, et al. Adv Ther. Published online March 13, 2025. doi:10.1007/s12325-025-03115-9